World Vaccine Congress, Europe

Following up WVC in Washington during the spring CSO Anna-Karin Maltais and CEO Hans Arwidsson will present the latest progress from development of Immunose™ FLU, our first vaccine candidate, based on our technology platform Endocine™

This conference is about research, development and strategic partnering for the global vaccine industry. Read more here =>